GED Capital, a private equity group focused on the Iberian lower mid-market segment, has acquired 100 per cent of the shares in health service providers High Research, Interactive Communication Projects, (3.Ways), and BCN Science from their respective founders and management teams.
GED Capital, a private equity group focused on the Iberian lower mid-market segment, has acquired 100 per cent of the shares in health service providers High Research, Interactive Communication Projects, (3.Ways), and BCN Science from their respective founders and management teams.
The investment has been made from the GED VI España fund and through its portfolio company Evidenze Group Europe (Evidenze).
These acquisitions reinforce the growth plan around the consolidation of value-added service providers in the healthcare sector, bringing together four main activities: (i) clinical studies, (ii) continuing medical education (iii) patient support programmes and (iv) specialised communication strategy and agency.
In addition, Evidenze continues its international expansion. In February 2021, Evidenze already acquired the Portuguese company Keypoint, a leading local CRO, which not only expanded the range of CRO services on an Iberian level, but also provided an entry platform in the country for the sale of medical training and patient support services.
The integration of these companies allows Evidenze to: strengthen its position in the value-added services sector for the healthcare sector and expand its clinical trial offering to other countries (Portugal and Italy) while maintaining its local CRO approach; expand the range of services and multimedia and innovation capabilities in an increasingly demanding environment; and strengthen a key strategic area for its clients, such as communication and agency consultancy.
Evidenze has therefore become a key partner, present with its client at the time of strategic decisions on a drug or medical device and accompanying them throughout the life of the product, offering the necessary tools at all times (communication/agency, clinical trials, training, patient support programmes). Evidenze has also become a distinguished player in the “Innovative Public Procurement” programmes launched by public administrations.
The acquisition of the eight companies that make up Evidenze in a period of seven months, compared to the two years initially planned, confirms the success of the Project and the sectorial recognition, not only at national level but also at a European level.
Enrique Centelles Satrústegui, managing partner of GED, says: “With these three acquisitions we take a new step towards our goal of creating a national leader with European presence through a buy&build strategy. Evidenze operates in a sector with high organic growth projected for the future, highly fragmented and highly digitalised, especially after the Covid-19 effect.”
Kerman Elordi, CEO of Evidenze, says: “With these additions we consolidate a differential proposal in the market, providing value during all stages of the life of the product, from its development during the research phase, to its launch on the market and its transfer to daily clinical practice.”
